These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 11081189

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
    Colao A, Marzullo P, Ferone D, Marinò V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A, Lombardi G.
    J Endocrinol Invest; 1999 Jan; 22(1):40-7. PubMed ID: 10090136
    [Abstract] [Full Text] [Related]

  • 3. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 4. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R, Attanasio R, Lodrini S, Lasio G.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
    [Abstract] [Full Text] [Related]

  • 5. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
    Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
    [Abstract] [Full Text] [Related]

  • 6. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients.
    Minniti G, Jaffrain-Rea ML, Baldelli R, Ferretti E, Caracciolo B, Bultrini A, Gulino A, Tamburrano G.
    Clin Ter; 1997 Dec; 148(12):601-7. PubMed ID: 9528195
    [Abstract] [Full Text] [Related]

  • 7. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
    Mattar P, Alves Martins MR, Abucham J.
    Neuroendocrinology; 2010 Dec; 92(2):120-7. PubMed ID: 20802256
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
    Giustina A, Mazziotti G, Cannavò S, Castello R, Arnaldi G, Bugari G, Cozzi R, Ferone D, Formenti AM, Gatti E, Grottoli S, Maffei P, Maffezzoni F, Montini M, Terzolo M, Ghigo E.
    J Clin Endocrinol Metab; 2017 Jul 01; 102(7):2454-2464. PubMed ID: 28419317
    [Abstract] [Full Text] [Related]

  • 10. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
    Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M.
    Clin Endocrinol (Oxf); 2008 Mar 01; 68(3):473-80. PubMed ID: 17941902
    [Abstract] [Full Text] [Related]

  • 11. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
    Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G.
    Eur J Endocrinol; 1999 Sep 01; 141(3):267-71. PubMed ID: 10474124
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
    Ambrosio MR, Franceschetti P, Bondanelli M, Doga M, Maffei P, Baldelli R, Tamburrano G, Sicolo N, Giustina A, degli Uberti EC.
    Metabolism; 2002 Mar 01; 51(3):387-93. PubMed ID: 11887179
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA.
    Clin Endocrinol (Oxf); 2005 Mar 01; 62(3):282-8. PubMed ID: 15730408
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.
    Vilar L, Azevedo MF, Naves LA, Casulari LA, Albuquerque JL, Montenegro RM, Montenegro RM, Figueiredo P, Nascimento GC, Faria MS.
    Pituitary; 2011 Jun 01; 14(2):148-56. PubMed ID: 21104199
    [Abstract] [Full Text] [Related]

  • 17. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
    Puig-Domingo M, Soto A, Venegas E, Vilchez R, Blanco C, Cordido F, Lucas T, Marazuela M, Casany R, Cuatrecasas G, Fajardo C, Gálvez MÁ, Maraver S, Martín T, Romero E, Paja M, Picó A, Bernabeu I, Resmini E, ACROCOMB study group.
    Endocrinol Nutr; 2016 Oct 01; 63(8):397-408. PubMed ID: 27448708
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M, Gussoni G, Cuttica CM, Giordano G.
    J Clin Endocrinol Metab; 1996 Jun 01; 81(6):2089-97. PubMed ID: 8964833
    [Abstract] [Full Text] [Related]

  • 19. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
    Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK, Aydin Y, Guler S.
    Pituitary; 2012 Sep 01; 15(3):398-404. PubMed ID: 21863263
    [Abstract] [Full Text] [Related]

  • 20. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P.
    J Clin Endocrinol Metab; 1994 Jul 01; 79(1):145-51. PubMed ID: 8027218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.